gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLC10.22416/1382-4376-2021-31-6-41-46gastro-j-585Research ArticleНАЦИОНАЛЬНАЯ ШКОЛА ГАСТРОЭНТЕРОЛОГИИ, ГЕПАТОЛОГИИNATIONAL COLLEGE OF GASTROENTEROLOGY, HEPATOLOGYПостинфекционный синдром раздраженного кишечника: спорные и нерешенные вопросыPostinfectious Irritable Bowel Syndrome: Polemic and Open Issueshttps://orcid.org/0000-0002-1395-9566ШептулинАркадий АлександровичSheptulinA. A.

Шептулин Аркадий Александрович — доктор медицинских наук, профессор кафедры пропедевтики внутреннихболезней, гастроэнтерологии и гепатологии Института клинической медицины им. Н.В. Склифосовского,

119435, г. Москва, ул. Погодинская ул., д. 1, стр. 1

Arkadiy A. Sheptulin — Dr. Sci. (Med.), Prof., Chair of Internal Disease Propaedeutics, Gastroenterology and Hepatology, Sklifosovsky Institute of Clinical Medicine,

119435, Moscow, Pogodinskaya str., 1, bld. 1

arkalshep@gmail.comhttps://orcid.org/0000-0002-0960-1166Визе-ХрипуноваМарина АнатольевнаVize-KhripunovaM. A.

Визе-Хрипунова Марина Анатольевна  — кандидат медицинских наук, доцент, заведующая кафедрой госпитальнойтерапии медицинского факультета Института медицины, экологии и физической культуры,

432017, г. Ульяновск, ул. Льва Толстого, д. 42

Marina A. Vize-Khripunova  — Cand. Sci. (Med.), Assoc. Prof., Head of the Chair of Hospital Therapy, Faculty of Medicine, Institute of Medicine, Ecology and Physical Education, 

432017, Ulyanovsk, L. Tolstogo str., 42

vize-marina@yandex.ruФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» (Сеченовский Университет) Министерства здравоохранения Российской ФедерацииРоссияSechenov First Moscow State Medical University (Sechenov University)Russian FederationФГБОУ ВО «Ульяновский государственный университет» Министерства науки и высшего образования Российской ФедерацииРоссияUlyanovsk State UniversityRussian Federation2021070320223164146Copyright © Шептулин А.А., Визе-Хрипунова М.А., 20222022Шептулин А.А., Визе-Хрипунова М.А.Sheptulin A.A., Vize-Khripunova M.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/585Цель обзора

Цель обзора. Проанализировать спорные и нерешенные вопросы, касающиеся эпидемиологии, патогенеза, клиники, диагностики и лечения постинфекционного синдрома раздраженного кишечника (СРК).

Основные положения

Основные положения. Частота постинфекционного СРК зависит от того, какой этиологический фактор привел к развитию острого инфекционного гастроэнтерита (бактерии, вирусы, простейшие). Идентифицированы факторы риска формирования постинфекционного СРК: женский пол, повышенный уровень тревоги, депрессии и соматизации, тяжелое течение острого инфекционного гастроэнтерита и др. Диагноз постинфекционного СРК предполагает исключение органических заболеваний, протекающих со сходной клинической картиной. Специальное лечение больных с постинфекционным СРК не разработано, и оно строится в соответствии с принципами лечения «непостинфекционного» СРК.

Заключение

Заключение. Проблема постинфекционного СРК изучена недостаточно и требует продолжения исследований. 

Aim

Aim. An analysis of polemic and open topics in epidemiology, pathogenesis, clinic, diagnosis and treatment of postinfectious irritable bowel syndrome (IBS).

Key points

Key points. The incidence of postinfectious IBS links to aetiological factors underlying the development of acute infectious gastroenteritis (bacteria, viruses or protozoans). The risk factors of postinfectious IBS have been identified: female gender, excessive anxiety, depression and somatisation, a severe sequence of acute infectious gastroenteritis, etc. The diagnosis of postinfectious IBS implies exclusion of organic diseases with similar clinical presentations. A specific postinfectious IBS treatment is currently lacking and adheres to non-postinfectious IBS strategies.

Conclusion

Conclusion. The postinfectious IBS problematic is poorly understood and requires further research. 

постинфекционный синдром раздраженного кишечникафакторы рискадиагностикаpostinfectious irritable bowel syndromerisk factorsdiagnosisReferencesChaudhary N.A., Truelove S.C. The irritable colon syndrome. A study of the clinical features, predisposing causes and prognosis in 130 cases. Q J Med. 1962;31:307–22.Chaudhary N.A., Truelove S.C. The irritable colon syndrome. A study of the clinical features, predisposing causes and prognosis in 130 cases. Q J Med. 1962;31:307–22.Riddle M.S., Connor P., Porter C.K. Montezuma’s revenge — the sequel: The one-hundred year anniversary of the first description of “post-infectious” irritable bowel syndrome. World J Gastroenterol. 2018;24(45):5076–80. DOI: 10.3748/wjg.v24.i45.5076Riddle M.S., Connor P., Porter C.K. Montezuma’s revenge — the sequel: The one-hundred year anniversary of the first description of “post-infectious” irritable bowel syndrome. World J Gastroenterol. 2018;24(45):5076–80. DOI: 10.3748/wjg.v24.i45.5076Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R. Bowel disorders. Gastroenterology. 2016;150:1393–407. DOI: 10.1053/j.gastro.2016.02.031Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R. Bowel disorders. Gastroenterology. 2016;150:1393–407. DOI: 10.1053/j.gastro.2016.02.031Barbara G., Grover M., Bercik P., Corsetti M., Ghoshal U.C., Ohman L., Rajilic-Stojanovic M. Rome Foundation Working Team report on post-infection irritable bowel syndrome. Gastroenterology. 2019;156(1):46– 58. DOI: 10.1053/j.gastro.2018.07.011Barbara G., Grover M., Bercik P., Corsetti M., Ghoshal U.C., Ohman L., Rajilic-Stojanovic M. Rome Foundation Working Team report on post-infection irritable bowel syndrome. Gastroenterology. 2019;156(1):46– 58. DOI: 10.1053/j.gastro.2018.07.011Klem F., Wadhwa A., Prokop L.J., Sundt W.J., Farrugia G., Camilleri M., et al. Prevalence, risk factors and outcomes of irritable bowel syndrome after infectious enteritis: a systemic review and meta-analysis. Gastroenterology. 2017;152(5):1042–54. DOI: 10.1053/j.gastro.2016.12.039Klem F., Wadhwa A., Prokop L.J., Sundt W.J., Farrugia G., Camilleri M., et al. Prevalence, risk factors and outcomes of irritable bowel syndrome after infectious enteritis: a systemic review and meta-analysis. Gastroenterology. 2017;152(5):1042–54. DOI: 10.1053/j.gastro.2016.12.039Dayananda P., Wilcox M.H. Irritable bowel syndrome following Clostridium difficile infection. Curr Opin Gastroenterol. 2019;35(1):1–5. DOI: 10.1897/MOG.0000000000000490Dayananda P., Wilcox M.H. Irritable bowel syndrome following Clostridium difficile infection. Curr Opin Gastroenterol. 2019;35(1):1–5. DOI: 10.1897/MOG.0000000000000490Zanini B., Ricci C., Bandera F., Caselani F., Magni A., Laronga A.M., et al. Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak. Am J Gastroenterol. 2012;107(6):891–8. DOI: 10.1038/ajg.2012.102Zanini B., Ricci C., Bandera F., Caselani F., Magni A., Laronga A.M., et al. Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak. Am J Gastroenterol. 2012;107(6):891–8. DOI: 10.1038/ajg.2012.102Noviello D. Costantino A., Muscatello A., Bandera A., Consonni D., Vecchi M., Basilisko G. Functional gastrointestinal and somatoform symptoms four month after SARS-CoV-2 infection: A controlled cohort study. Neurogastroenterol Motil. 2021;e14187. DOI: 10.1111/nmo.14187Noviello D. Costantino A., Muscatello A., Bandera A., Consonni D., Vecchi M., Basilisko G. Functional gastrointestinal and somatoform symptoms four month after SARS-CoV-2 infection: A controlled cohort study. Neurogastroenterol Motil. 2021;e14187. DOI: 10.1111/nmo.14187Kanazawa M., Palsson O.S., van Tiburg M.A.L., Gangarosa L.M., Fukudo S., Rhitehead W.E. Motility response to colonic distention is increased in postinfectious irritable bowel syndrome (PI-IBS). Neurogastroenterol Motil. 2014;26(5):6960704. DOI: 10.1111/nmo.12318Kanazawa M., Palsson O.S., van Tiburg M.A.L., Gangarosa L.M., Fukudo S., Rhitehead W.E. Motility response to colonic distention is increased in postinfectious irritable bowel syndrome (PI-IBS). Neurogastroenterol Motil. 2014;26(5):6960704. DOI: 10.1111/nmo.12318Jalanka J., Salonen A., Fuentes S. de Vos W.M. Microbial signatures in post-infectious irritable bowel syndrome — toward patient stratification for improved diagnostics and treatment. Gut Microbes. 2015;6(6):364–9. DOI: 10.1080/19490976.2015.1096486Jalanka J., Salonen A., Fuentes S. de Vos W.M. Microbial signatures in post-infectious irritable bowel syndrome — toward patient stratification for improved diagnostics and treatment. Gut Microbes. 2015;6(6):364–9. DOI: 10.1080/19490976.2015.1096486Spiller R.C., Jenkins D., Thornley J.P., Hebden J., Wright T., Skinner M., et al. Increased rectal mucosal enteroendocrine cells, T-lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47(6):804–11. DOI: 1136/gut.47.6.804Spiller R.C., Jenkins D., Thornley J.P., Hebden J., Wright T., Skinner M., et al. Increased rectal mucosal enteroendocrine cells, T-lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47(6):804–11. DOI: 1136/gut.47.6.804Wang L.-H., Fang X.-C., Pan G.-Z. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut. 2004;53(8):1096–101. DOI: 10.1136/gut.2003.021154Wang L.-H., Fang X.-C., Pan G.-Z. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut. 2004;53(8):1096–101. DOI: 10.1136/gut.2003.021154Chen J.I. Chen J.I., Zhang Y., Deng Z. Imbalanced shift of cytokine expression between T helper 1 and T helper 2 (Th1/Th2) in intestinal mucosa of patients with postinfectious irritable bowel syndrome. BMC Gastroenterol. 2012;12:91.Chen J.I. Chen J.I., Zhang Y., Deng Z. Imbalanced shift of cytokine expression between T helper 1 and T helper 2 (Th1/Th2) in intestinal mucosa of patients with postinfectious irritable bowel syndrome. BMC Gastroenterol. 2012;12:91.Ивашкин В.Т., Шелыгин Ю.А., Баранская Е.К., Белоусова Е.А., Бениашвили А.Г., Васильев С.В. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению синдрома раздраженного кишечника. Рос журн гастроэнтерол гепатол колопроктол. 2017;27(5):76-93.Ivashkin V.T., Shelygin Yu. A., Baranskaya E.K., Belousova Ye. A., Beniashvili A.G., Vasilyev S.V., et al. Diagnosis and treatment of the irritable bowel syndrome: clinival guidelines of the Russian gastroenterological association and Russian association of coloproctology. Rus J Gastroenterol Hepatol Coloproctol. 2017;27(5):76–93 (In Russ.).Shah A., Talley N.J., Jones M, Kendall BJ, Lolosri N, Walker M.M., et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis of case-control studies. Am J Gastroenterol. 2020;115(2):190–201. DOI: 10.14309/ajg.0000000000000504Shah A., Talley N.J., Jones M, Kendall BJ, Lolosri N, Walker M.M., et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis of case-control studies. Am J Gastroenterol. 2020;115(2):190–201. DOI: 10.14309/ajg.0000000000000504Esposito I., de Leone A., Di Gregorio S., de Magistris L., Ferrieri A., Riegler G. Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. World J Gastroenterol. 2007;13(45):6016–21. DOI: 10.3748/wjg.v13.45.6016Esposito I., de Leone A., Di Gregorio S., de Magistris L., Ferrieri A., Riegler G. Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. World J Gastroenterol. 2007;13(45):6016–21. DOI: 10.3748/wjg.v13.45.6016Самсонов А.А., Плотникова Е.Ю., Борщ М.В. Постинфекционный синдром раздраженного кишечника — особая форма функциональной кишечной патологии. Лечащий врач. 2012;7:21–9.Samsonov A.A., Plotnikova E.Yu., Borsch M.V. Postinfectious irritable bowel syndrome I — a special form of functional intestinal pathology. Lechastshiy vrach. 2012;7:21–9 (In Russ.).Cremon C., Stanghellinu V., Pallotti F., Fogacci E., Bellacosa L., Morselli-Lobato A.M., et al. Salmonella gastroenteritis during childhood is a risk factor for irritable bowel syndrome in adulthood. Gastroenterology. 2014;147(1):69–77. DOI: 10.1053/j.gastro.2014.03.013Cremon C., Stanghellinu V., Pallotti F., Fogacci E., Bellacosa L., Morselli-Lobato A.M., et al. Salmonella gastroenteritis during childhood is a risk factor for irritable bowel syndrome in adulthood. Gastroenterology. 2014;147(1):69–77. DOI: 10.1053/j.gastro.2014.03.013Jin Y., Ren X., Li G., Li Y., Zhang L, Wang H., et al. Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota. J Gastroenterol Hepatol. 2018;33(2):443–52. DOI: 10.1111/jgh.13841Jin Y., Ren X., Li G., Li Y., Zhang L, Wang H., et al. Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota. J Gastroenterol Hepatol. 2018;33(2):443–52. DOI: 10.1111/jgh.13841Сuoco L., Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol Dietol. 2006;52(1):89–95.Сuoco L., Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol Dietol. 2006;52(1):89–95.Peralta S., Cottone C., Doveri T., Almasio P.L., Craxi A. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin. World J Gastroenterol. 2009;15(21):2628–31. DOI: 10.3748/wjg.15.2628Peralta S., Cottone C., Doveri T., Almasio P.L., Craxi A. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin. World J Gastroenterol. 2009;15(21):2628–31. DOI: 10.3748/wjg.15.2628Leventogiannis K., Gkolfakis P., Spithakis G., Tsatali A., Pistiki A., Sioulas A., et al. Effect of a preparation of four probiotics on symptoms of patients with irritable bowel syndrome: association with intestinal bacterial overgrowth. Probiotics Antimicrob Proteins. 2019;11(2):627– 34. DOI: 10.1007/s12602-018-9401-3Leventogiannis K., Gkolfakis P., Spithakis G., Tsatali A., Pistiki A., Sioulas A., et al. Effect of a preparation of four probiotics on symptoms of patients with irritable bowel syndrome: association with intestinal bacterial overgrowth. Probiotics Antimicrob Proteins. 2019;11(2):627– 34. DOI: 10.1007/s12602-018-9401-3

The authors declare that there are no conflicts of interest present.